BioInvent International
25.11.2021 08:51:35 CET | ACCESS Newswire | Press release
LUND, SWEDEN / ACCESSWIRE / November 25, 2021 / BioInvent International (STO:BINV)
Lund, Sweden - November 25, 2021 - The members of the Nomination Committee for BioInvent International AB:s (publ) ("BioInvent") Annual General Meeting in 2022 have now been appointed.
The following representatives of BioInvent International AB's shareholders will be members of the Nomination Committee for the Annual General Meeting 2022:
- Laura Feinleib, appointed by Redmile Group, LLC
- Erik Esveld, appointed by van Herk Investments B.V.
- Vincent Ossipow, appointed by Omega Funds, LP
- Leonard Kruimer, Chairman of the Board
The Nomination Committee shall prepare proposals for the Annual General Meeting in 2022 regarding Chairman of the General Meeting, Chairman of the Board and other Board members, board remuneration shared among the Chairman and other Board members, possible compensation for committee work, and election of auditors and auditor's fees.
The Annual General Meeting will be held on April 28, 2022 in Lund, Sweden.
Proposals to the Nomination Committee can be sent to Stefan Ericsson, by mail: BioInvent International AB (publ).), SE-223 70 Lund or telephone: +46 (0)46-46 286 85 50 in good time before March 10, 2022
For further information, please contact:
Cecilia Hofvander
Senior Director Investor Relations
Tel: +46 46 286 85 50
Email. cecilia.hofvander@bioinvent.com
BioInvent International AB (publ)
Co. Reg. No. Org nr: 556537-7263
Visiting address: Ideongatan 1
Mailing address: 223 70 LUND
Phone: +46 (0)46 286 85 50
www.bioinvent.com
About BioInvent
BioInvent International AB (Nasdaq Stockholm: BINV) is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently three drug candidates in four ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors, respectively. The Company's validated, proprietary F.I.R.S.T™ technology platform simultaneously identifies both targets and the antibodies that bind to them, generating many promising new drug candidates to fuel the Company's own clinical development pipeline or for additional licensing and partnering.
The Company generates revenues from research collaborations and license agreements with multiple top-tier pharmaceutical companies, as well as from producing antibodies for third parties in the Company's fully integrated manufacturing unit. More information is available at www.bioinvent.com. Follow us on Twitter: @BioInvent.
SOURCE: BioInvent International
View source version on accesswire.com:
https://www.accesswire.com/674695/Nomination-Committee-Appointed-for-BioInvent-Internationals-Annual-General-Meeting-2022
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Suntex Enterprises Launches Ambitious $1 Billion+ North American Real Estate Development Initiative4.9.2026 13:30:00 CEST | Press release
Two major Alberta projects are projected to generate approximately $575 million in revenue as Suntex expands its integrated development, construction, and ownership platform throughout Canada and the United States. AUSTIN, TX / ACCESS Newswire / September 4, 2026 / Suntex Enterprises, Inc. (OTCID:SNTX) ("Suntex" or the "Company"), a dynamic operating and holding company dedicated to real estate development, construction, infrastructure, and land, proudly announces the signing of a Letter of Intent ("LOI") that advances a transformative multiyear real estate development partnership across North America. The LOI builds upon the Canadian development relationship unveiled by Suntex in July 2026 and lays the groundwork for a robust initial portfolio of large-scale development opportunities designed to drive substantial growth across the Company's expanding North American platform. The portfolio is anchored by Royal Links in Leduc, Alberta, and Meridian in Alberta, representing $575 million
Formerra Receives 2026 Eaton Supplier Excellence Award3.9.2026 16:45:00 CEST | Press release
Recognition places Formerra among several dozen honorees from a supplier network of more than 30,000. ROMEOVILLE, IL / ACCESS Newswire / September 3, 2026 / Formerra, a leader in performance materials distribution, was recognized for its partnership at Eaton's 2026 Global Supplier Conference & Excellence Awards, held Thursday, August 27 in Beachwood, Ohio. Formerra was one of only 30 suppliers recognized with Eaton's Supplier Excellence Award from among the company's global network of more than 30,000 supplier partners. Eaton grants the Supplier Excellence Award to suppliers that exceed expectations through exceptional performance, innovation, and contributions to growth. Formerra serves as Eaton's preferred plastics distribution partner, a role built through disciplined execution and engagement across Eaton's corporate organization and manufacturing sites. While the partnership began over 15 years ago in North America, it now extends into Asia, Europe, and the Middle East, where Forme
DistillerSR Joins European MedTech Consortium to Digitalize Medical Device and IVD Conformity Assessments3.9.2026 16:00:00 CEST | Press release
€4 million European-funded DIGICAP project brings together 19 organizations to replace document-based conformity assessments with machine-readable data. DistillerSR named one of five technology providers building the framework. OTTAWA, ON / ACCESS Newswire / September 3, 2026 / DistillerSR, the market leader in AI-enabled literature review automation and evidence management, today announced its participation in DIGICAP (DIGItalisation of the Conformity Assessment Process), a €4 million European initiative uniting 19 organizations across 12 EU countries to digitalize how medical devices and in vitro diagnostics are certified for the European market. The project is funded under Horizon Europe, the world's largest multinational research and innovation program, with a budget of €95.5 billion for the 2021-2027 period. DistillerSR is one of five regulatory technology providers selected to support the project, alongside Veeva, MEDDEVO, AUREVIA and Hardian Health. The company will work in the
U.S. Polo Assn. Marks Continued Success as Title Sponsor of the 2026 Pacific Coast Open3.9.2026 13:00:00 CEST | Press release
Historic Championship Brings Together Elite Competition, California Lifestyle, and the Authentic Spirit of the Sport of Polo SANTA BARBARA, CA / ACCESS Newswire / September 3, 2026 / U.S. Polo Assn.®, the official sports brand of the United States Polo Association (USPA), celebrated the conclusion of the 2026 U.S. Polo Assn. Pacific Coast Open, held August 14-30 at the renowned Santa Barbara Polo & Racquet Club in Carpinteria, California. As one of the oldest polo tournaments in the world and the most prestigious championship in the Western United States, the Pacific Coast Open once again delivered world-class competition while highlighting the enduring connection between sport, style, and community. 2026 U.S. Polo Assn. Pacific Coast Open Winners, Klentner Ranch, on stage with trophy; Photo Credit: Michelle Lauren This year marked the second time U.S. Polo Assn. served as Title Sponsor of the Pacific Coast Open and the ninth consecutive year partnering with the Santa Barbara Polo & Ra
CubeLogic Launches a New Generation of Credit Risk Technology with RiskCubed Version 123.9.2026 11:00:00 CEST | Press release
The most significant technology shift in CubeLogic's history - delivering real-time performance, natural language reporting, and AI built directly into the platform. LONDON, UK / ACCESS Newswire / September 3, 2026 / CubeLogic, the leading provider of enterprise risk and compliance software for trading organisations across the energy and commodities sector, today launched Version 12 (V12) of its RiskCubed platform - bringing real-time, AI-powered credit risk management to a market that has long depended on overnight processing. Built on modern, cloud-native foundations, V12 re-architects how RiskCubed stores data, delivers reporting, runs margining and scales to meet demand. For credit teams, that changes the working day as well as the technology behind it: exposure positions can be reviewed as they update rather than waiting on a batch, and reports that previously required a specialist can be built in the moment. "We are excited to partner with our clients in developing the next gener
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom